120 Chinese Hospitals, One Coordinated Route In

A full-process patient-coordination platform for cross-border medical services into China. It is not a hospital and holds no medical-institution licence: it does not perform diagnosis, write prescriptions or deliver clinical treatment. What it does is the non-clinical work — pre-reviewing the case, matching hospitals, arranging consultations, handling invitation-letter documentation, interpretation and escort on the ground, and follow-up afterwards. Every diagnosis, therapy and legally significant medical document comes from a licensed hospital and a practising physician in China.

There is no list price on this page, and that is deliberate rather than evasive. The regimen, the number of sessions and the final cost all follow the delivering hospital’s own clinical evaluation and its latest written quotation, so any figure published in advance would be fiction. Once your records are substantially complete you receive a free preliminary cost estimate and a written quotation — an estimate, not a fixed medical price, and not the same thing as the final hospital bill.

For applications that are complete, well documented and judged clinically relevant, one complimentary online medical consultation can be arranged. You submit imaging, laboratory reports and your prior treatment history; specialists from Chinese hospitals then give a preliminary online assessment, with reference-level suggestions on treatment pathways in China and on which hospitals would suit the case. It is for reference only — it is not an official hospital diagnostic report. It is also subject to the hospital confirming the attending physician, the duration and the appointment schedule; not all cases qualify; it is in principle once per approved patient; and it cannot be exchanged for cash.

No, and nobody honestly can. The hospital network reflects coordination access, not ownership or exclusive rights. Bed availability, specialist schedules, clinical acceptance, international-patient policies and prices must be re-verified case by case, and only a formal written confirmation from the hospital itself constitutes an admission intention. Anything before that is a working assumption.

That is a hospital’s decision, made against strict indications and contraindications, and it is made on documents you have not sent yet. For oncology immunotherapy, complete pathology, tumour staging, molecular testing and full prior-treatment records are required and a multidisciplinary tumour team evaluation is mandatory. For gene therapy and rare disease, full genetic-testing reports are required, with pathogenic variants and the relevant organ or visual function confirmed by specialists in that field. For stem-cell and immune-cell therapy, hospitals screen for active infection, severe organ-function impairment, coagulation risk and immune status before any therapeutic evaluation.

No. Oncology immunotherapy in this catalogue must not replace standard anti-tumour treatment and must not delay necessary conventional care. It is assessed as something that sits alongside your existing pathway, and any hospital that told you otherwise would be telling you something the programme rules do not allow.

They solve different problems. Public Grade-A tertiary hospitals bring very large clinical volumes and deep expert teams, which is what difficult, severe and complex cases need; but admission, specialists, beds, scheduling and international-service policies are entirely the hospital’s to set. Private and international hospitals offer flexible scheduling, mature international services and better privacy, though specialty capability varies and fees are usually higher. Most of the cell and gene therapy programmes and the special-access-drug work are delivered inside the private specialty centres. A cross-hospital MDT is the third option, pulling opinions and treatment from several hospitals into one pathway with your consent, at the cost of extra coordination.

Not on request, no. The platform collects patient medical information for preliminary matching only. It does not directly recommend prescription drugs and gives no stock-availability guarantees. Whether a medicine from the special-access list can be applied for at all, and whether its indications and contraindications fit you, is assessed independently by physicians at the receiving hospital. Nothing on this page is a prescription, a drug advertisement, an efficacy promise or a stock guarantee.

The public hospital list spans Beijing, Shanghai, Guangzhou, Chengdu, Chongqing, Changsha, Wuhan, Hangzhou, Nanjing, Suzhou, Jinan, Qingdao, Tianjin, Xi’an, Changchun, Shenyang, Harbin and Zhengzhou, and coordination runs across Beijing, Shanghai, Guangzhou, Shenzhen, Chengdu, Chongqing and Hainan as the main destinations. Which city you go to follows from which hospital can actually take your case — not the other way round.

Discharge medical records are organised and remote follow-up with the attending physicians is facilitated after you return, alongside the remaining administrative items. Cross-border treatment that ends at the airport is not treatment that has been coordinated properly.

MedVoyage Global. We obtain your authorisation, collect the records accurately, clarify your budget, timing and location preferences, and explain what comes back without dressing it up. We are also prohibited from making unauthorised promises about efficacy, scheduling or a fixed total price — so if an answer sounds carefully bounded, that is why.

None, and you should be suspicious of anyone who offers one. Strict indications and contraindications apply across every programme, no therapeutic-effect guarantees are given, and all diagnoses, treatment plans, surgeries, prescriptions and clinical decisions are made independently by legally qualified hospitals and doctors. Neither Medora Health nor MedVoyage Global provides medical diagnosis, and neither guarantees hospital admission, a specific doctor, a treatment effect, a recovery time or a cure.